- Home
- CRDO vs LNTH Comparison
CRDO vs LNTH Comparison
Compare CRDO & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRDO | LNTH |
|---|---|---|
| Founded | 2008 | 1956 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 4.9B |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CRDO | LNTH |
|---|---|---|
| Price | $96.03 | $76.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $176.36 | $83.20 |
| AVG Volume (30 Days) | ★ 6.7M | 1.0M |
| Earning Date | 03-02-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 261.11 | N/A |
| EPS | 1.62 | ★ 3.41 |
| Revenue | ★ $436,775,000.00 | $343,374,000.00 |
| Revenue This Year | $210.92 | N/A |
| Revenue Next Year | $52.72 | $13.93 |
| P/E Ratio | $57.98 | ★ $22.25 |
| Revenue Growth | ★ 126.34 | 3.62 |
| 52 Week Low | $29.09 | $47.27 |
| 52 Week High | $213.80 | $108.86 |
Technical Indicators
Market Signals| Indicator | CRDO | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 50.90 |
| Support Level | $91.74 | $72.33 |
| Resistance Level | $104.35 | $84.77 |
| Average True Range (ATR) | 7.49 | 2.70 |
| MACD | -0.77 | -0.69 |
| Stochastic Oscillator | 24.01 | 31.10 |
Price Performance
Historical ComparisonAbout CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.